Clinical Trial Update: A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: [Phase 4]

View source ↗

Summary

Phase 4 pharmacodynamic study comparing prasugrel and ticagrelor in PCI patients with CYP2C19 loss-of-function completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PRASUGREL (prasugrel)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED | Results posted: 2020-08-20